Novel drug - dinutuximab for high-risk neuroblastoma

Novel drug - dinutuximab for high-risk neuroblastoma

Neuroblastoma is the most common extracranial tumor in children aged <5 years. Prognosis of high-risk neuroblastoma is not good even after use of aggressive chemotherapy. Newer drug anti-GD2 monoclonal antibodies, dinutuximab in combination with granulocyte-macrophage colony-stimulating factor or...

Full description

Bibliographic Details
Main Authors: Supriya Kushwah, Ashutosh Kumar, S Shabnam
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Apollo Medicine
Subjects:
antibody-dependent cell-mediated cytotoxicity
anti-gd2 monoclonal antibodies
dinutuximab
extracranial tumor
neuroblastoma
Online Access:http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah

Internet

http://www.apollomedicine.org/article.asp?issn=0976-0016;year=2018;volume=15;issue=3;spage=132;epage=134;aulast=Kushwah

Similar Items